Tiny early trial launches for new autoimmune drug
NCT ID NCT07193810
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new biologic drug called CC312 in just 6 adults with lupus, myositis, or scleroderma that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive multiple IV infusions over two weeks and are monitored closely for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CC312 (a biologic drug given by IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat autoimmune diseases like lupus.
- What could go wrong
- This is a very early, tiny trial (only 6 people) focused on safety. It is far from proving effectiveness, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Deyang People's Hospital
RECRUITINGDeyang, Sichuan, 618000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Engineered immune cells take aim at Hard-to-Treat muscle disease
- Engineered immune cells take aim at childhood autoimmune diseases
- New study aims to unlock secrets of rare muscle disease
- HIV drug repurposed to fight muscle inflammation
- New injection aims to tame stubborn autoimmune diseases